ALFA Filings
Every announcement, straight from the exchange
Every Sandu Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements with these filters
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
Sandu Pharmaceuticals filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with minor previous reporting delays noted.
Sandu Pharmaceuticals Ltd confirmed it is not classified as a 'Large Corporate' under SEBI's debt-raising framework for FY 2025-26. The company reported zero outstanding and incremental borrowings for the period ending March 31, 2026.
Sandu Pharmaceuticals Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company confirmed that securities received for dematerialisation during the quarter ended March 31, 2026, were processed and listed on the exchange. This is a routine regulatory filing with no material financial impact.